24/7 Customer Support

Asia Pacific Continuous Glucose Monitoring Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2031

Asia Pacific Continuous Glucose Monitoring Market: By Component (Sensors, Transmitters & Receivers, Integrated Insulin Pumps, and Others); Demographics (Child Population (<14 years) and Adult Population (>14 years)); End Users (Diagnostics/Clinics, ICUs, and Home Healthcare); and Country—Industry Dynamics, Market Size and Opportunity Forecast until 2031

  • Published Date: Mar-2023  |   Format: pdfpowerpointexcel  |  Report ID: AA0522220  | Delivery: 2 to 4 Hours
INFOGRAPHIC:
Asia Pacific Continuous Glucose Monitoring Market

View Full Infographic

REPORT SCOPE

Report AttributeDetails
Market Size Value in 2022US$ 1,179.9 Million
Expected Revenue in 2031US$ 3,309.7 Million
Historic Data2018-2021
Base Year2022
Forecast Period2023-2031
UnitValue (USD Mn)
CAGR12.22% 
Segments coveredBy Component, By Demographics, By End-User, By Country
Key Companies                                                                                 Abbott Laboratories, DexCom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd., Other Prominent Players
Customization ScopeGet your customized report as per your preference. Ask for customization

FREQUENTLY ASKED QUESTIONS

Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night on a continual basis by insulin-requiring people with diabetes. 

A continuous glucose monitor consists of three parts: a small electrode placed under the skin, a transmitter sending readings at regular intervals (ranging from every 5 to 15 min), and a separate receiver.

China has the highest prevalence of diabetes in Asia Pacific. 

The Asia Pacific Continuous Glucose Monitoring Market was valued at US$ 1,179.9 Mn in 2022. 

The Asia Pacific CGM market is projected to expand at a CAGR of 12.22% over the forecast period 2023-2031. 

The market is majorly driven by factors such as increased awareness among people towards monitoring and preventive health and surge in diabetic population.

CGM devices can be expensive, and the results might not be as accurate as a fingerstick check.

Sensors dominate the market in 2022.

Home healthcare segment are the highest end-users in the Asia Pacific Continuous Glucose Monitoring Market in 2022. 

China dominates the Asia Pacific CGM market.

India records the highest CAGR in the Asia Pacific CGM market. 

The key players in the Asia Pacific CGM market are Medtronic Plc, Abbott Lab, DexCom Inc., Senseonics Holding Inc., and Johnson & Johnson among others.

LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.

SPEAK TO AN ANALYST